PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study
PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study. // The Lancet Medical Imaging & Theranostics. – URL: https://www.sciencedirect.com/science/article/pii/S3117452326000109?dgcid=rss_sd_all
PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study. The Lancet Medical Imaging & Theranostics. https://www.sciencedirect.com/science/article/pii/S3117452326000109?dgcid=rss_sd_all
“PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study.” The Lancet Medical Imaging & Theranostics.
@article{article68706,
title = {PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I\&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study},
journal = {The Lancet Medical Imaging \& Theranostics},
url = {https://www.sciencedirect.com/science/article/pii/S3117452326000109?dgcid=rss_sd_all}
}
ABSTRACT As leadership education continues to evolve, increasing attention has been given to fostering learners’ leadership identity, capacity, and efficacy. Drawing on collaborative conversations with 12 leadership educators...